Function Of Potential Cancer-Causing Gene Product Uncovered By Conaway Lab

Main Category: Cancer / Oncology
Also Included In: Liver Disease / Hepatitis;  Genetics
Article Date: 10 Aug 2009 - 1:00 PDT

email to a friend   printer friendly   opinions  

The Stowers Institute's Conaway Lab has uncovered a previously unknown function of a gene product called Amplified in Liver Cancer 1 (Alc1), which may play a role in the onset of cancer. The work is published in the Proceedings of the National Academy of Science Early Edition.

"We've been able to demonstrate that the protein encoded by the Alc1 gene is, in fact, a chromatin remodeling enzyme," explained Aaron Gottschalk, lead author on the paper and a University of Kansas Medical Center graduate student conducting research in the Conaway Lab. "By itself, this enzyme is inactive, but in the presence of a compound called NAD and another enzyme called poly (ADP-ribose) polymerase 1 (Parp1), its ability to move nucleosomes on DNA is strongly activated."

Parp1 uses NAD to build a polymeric molecule, poly(ADP-ribose), that is coupled to Parp1 itself or to other proteins. The team established that binding of a specific Alc1 region to poly(ADP-ribose) coupled to Parp1 helps recruit Alc1 to bind to and remodel nucleosomes.

"This finding is particularly interesting because Parp1 and poly(ADP-ribose) are known to play important roles in transcriptional regulation, DNA repair, and DNA replication, but how they do so is really not at all clear," said Ron Conaway, Ph.D., Investigator and co-senior author on the publication. "Finding that Parp1 and poly(ADP-ribose) recruit the chromatin remodeling enzyme Alc1 to chromatin and activate Alc1 activity suggests a mechanism by which they might function."

Medical researchers at universities and pharmaceutical companies are investigating Parp inhibitors for treatment of cancer and other diseases. The team has shown that Parp inhibitors block Alc1 activities in the test tube and cells, suggesting that the therapeutic activities of these inhibitors could be due in part to indirect affects on Alc1. If true, drugs that target Alc1 function could also be useful in the treatment of disease.

Additional contributing authors from the Stowers Institute include Stephanie Kong, Ph.D., Senior Research Associate; Jingji Jin, Ph.D., Senior Research Associate; Yong Cai, Research Specialist I; Selene Swanson, Research Specialist II; Michael Washburn, Ph.D., Director of Proteomics; Laurence Florens, Ph.D., Managing Director of Proteomics; and Joan Conaway, Ph.D., Investigator. Authors from the Gene Expression Unit of the European Molecular Biology Laboratory include Gyula Timinszky, Ph.D., and Andreas Ladurner, Ph.D.

Source:
Marie Jennings
Stowers Institute for Medical Research

• Additional
• References
• Citations